Amgen Competitors
| AMGN Stock | USD 368.02 1.82 0.50% |
Amgen vs Novartis Correlation
Very weak diversification
The correlation between Amgen Inc and NVS is 0.57 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Amgen Inc and NVS in the same portfolio, assuming nothing else is changed.
Moving against Amgen Stock
| 0.72 | QSI | QuantumSi | PairCorr |
| 0.72 | LYRA | Lyra Therapeutics | PairCorr |
| 0.61 | EDIT | Editas Medicine | PairCorr |
| 0.6 | GNLX | Genelux Common | PairCorr |
| 0.57 | KRRO | Frequency Therapeutics | PairCorr |
Amgen Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Amgen and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Amgen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Amgen Inc does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Amgen Stock performing well and Amgen Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Amgen's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 1.33 | 0.32 | 0.18 | 1.57 | 1.27 | 3.01 | 6.70 | |||
| PFE | 1.13 | 0.15 | 0.09 | 0.21 | 1.26 | 2.40 | 7.97 | |||
| SNY | 1.03 | (0.12) | 0.00 | (0.16) | 0.00 | 1.87 | 5.92 | |||
| MRK | 1.32 | 0.46 | 0.31 | 0.65 | 1.07 | 3.59 | 8.09 | |||
| DHR | 1.08 | (0.02) | (0.01) | 0.04 | 1.36 | 2.30 | 8.05 | |||
| BMY | 1.23 | 0.34 | 0.23 | 0.56 | 1.03 | 3.26 | 8.00 | |||
| NVO | 2.36 | (0.14) | 0.00 | (0.02) | 0.00 | 5.80 | 23.77 | |||
| BSX | 1.34 | (0.41) | 0.00 | 10.14 | 0.00 | 1.73 | 7.34 | |||
| GSK | 1.04 | 0.22 | 0.15 | 0.85 | 0.96 | 2.34 | 6.43 | |||
| NVS | 0.95 | 0.29 | 0.24 | 0.48 | 0.73 | 2.59 | 6.07 |
Cross Equities Net Income Analysis
Compare Amgen Inc and related stocks such as Gilead Sciences, Pfizer Inc, and Sanofi ADR Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | (4 M) | 2.8 B | 2.6 B | 3.1 B | 12.1 B | 18.1 B | 13.5 B | 4.6 B | 5.5 B | 5.4 B | 123 M | 6.2 B | 4.6 B | 5.7 B | 480 M | 552 M | 524.4 M |
| PFE | 579.7 M | 8.7 B | 9.8 B | 11.6 B | 9.1 B | 7 B | 7.2 B | 21.3 B | 11.2 B | 16.3 B | 9.2 B | 22.1 B | 31.4 B | 2.1 B | 8 B | 7.8 B | 7.8 B |
| SNY | 625 M | 5.6 B | 4.9 B | 3.7 B | 4.4 B | 4.3 B | 4.7 B | 8.4 B | 4.3 B | 2.8 B | 12.3 B | 6.2 B | 8.4 B | 5.4 B | 5.6 B | 7.8 B | 5 B |
| MRK | 539.9 M | 6.3 B | 6.2 B | 4.4 B | 11.9 B | 4.4 B | 3.9 B | 2.4 B | 6.2 B | 9.8 B | 7.1 B | 13 B | 14.5 B | 365 M | 17.1 B | 18.3 B | 19.2 B |
| DHR | 5.6 M | 2 B | 2.3 B | 2.7 B | 2.6 B | 2.6 B | 2.6 B | 2.5 B | 2.7 B | 2.6 B | 3.6 B | 6.4 B | 7.2 B | 4.7 B | 3.9 B | 3.6 B | 3.8 B |
| BMY | 1.1 B | 3.7 B | 2 B | 2.6 B | 2 B | 1.6 B | 4.5 B | 1 B | 4.9 B | 3.4 B | (9 B) | 7 B | 6.3 B | 8 B | (8.9 B) | (8.1 B) | (7.7 B) |
| NVO | 607.8 M | 17.1 B | 21.4 B | 25.2 B | 26.5 B | 34.9 B | 37.9 B | 38.1 B | 38.6 B | 39 B | 42.1 B | 47.8 B | 55.5 B | 83.7 B | 101 B | 98.5 B | 103.4 B |
| BSX | 41.8 M | 441 M | (4.1 B) | (121 M) | (119 M) | (239 M) | 347 M | 104 M | 1.7 B | 4.7 B | (82 M) | 1 B | 698 M | 1.6 B | 1.9 B | 2.1 B | 2.2 B |
| GSK | 400 M | 5.3 B | 4.5 B | 5.4 B | 2.8 B | 8.4 B | 912 M | 1.5 B | 3.6 B | 4.6 B | 5.7 B | 4.4 B | 15 B | 4.9 B | 2.6 B | 3 B | 3.7 B |
| NVS | 4.4 B | 8.9 B | 9.3 B | 9.2 B | 10.2 B | 17.8 B | 6.7 B | 7.7 B | 12.6 B | 11.7 B | 8.1 B | 24 B | 7 B | 14.8 B | 11.9 B | 13.7 B | 9.9 B |
Amgen Inc and related stocks such as Gilead Sciences, Pfizer Inc, and Sanofi ADR Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Amgen Inc financial statement analysis. It represents the amount of money remaining after all of Amgen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Amgen Competitive Analysis
The better you understand Amgen competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Amgen's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Amgen's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Amgen Competition Performance Charts
Five steps to successful analysis of Amgen Competition
Amgen's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Amgen Inc in relation to its competition. Amgen's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Amgen in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Amgen's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Amgen Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Amgen position
In addition to having Amgen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Amgen Correlation with its peers. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Amgen diversify its offerings? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amgen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.136 | Dividend Share 9.39 | Earnings Share 14.22 | Revenue Per Share | Quarterly Revenue Growth 0.124 |
Investors evaluate Amgen Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Amgen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Amgen's market price to deviate significantly from intrinsic value.
Understanding that Amgen's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amgen represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Amgen's market price signifies the transaction level at which participants voluntarily complete trades.